Skip to content

Net Income at other companies

LQD
Liquidia CorporationLQDA
$52.86M+238%
Revvity logo
RevvityRVTY
$40.72M-3.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$166.56M+1.8%
Roivant Sciences logo
Roivant SciencesROIV
-$313.7M-366%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$73.29M+4.9%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$22.59M+165%

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.6B+96.7%

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ligand Pharmaceuticals's net income?
Ligand Pharmaceuticals (LGND) reported net income of -$13.35M in Q1 2026.
How has Ligand Pharmaceuticals's net income changed year-over-year?
Ligand Pharmaceuticals's net income increased by 68.6% year-over-year, from -$42.45M to -$13.35M.
What is the long-term trend for Ligand Pharmaceuticals's net income?
Over 4 years (2021 to 2025), Ligand Pharmaceuticals's net income has grown at a 18.8% compound annual growth rate (CAGR), from $62.55M to $124.45M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.